Enzalutamide significantly improves overall survival (OS) of patients with metastatic hormone- sensitive prostate cancer (mHSPC). However, ∼10% of patients will die within 2 years. PCPro is a plasma l...

This cohort study evaluates the time necessary to accurately document a persistent prostate-specific antigen level after radical prostatectomy.

Positron emission tomography (PET) with prostate-specific membrane antigen (PSMA) radioligands has an established role in the assessment of recurrence…

Despite treatment advances, most patients with metastatic hormone-sensitive prostate cancer (mHSPC) experience disease progression to castration-resistant disease within 5 years. The placebo-controlled, double-blind, phase III KEYNOTE-991 study evaluated the efficacy and safety of adding pembrolizumab to enzalutamide and androgen deprivation therapy (ADT) in participants with mHSPC.

This nonrandomized clinical trial evaluates physician-reported late toxic effects and 2-year patient-reported outcomes following post–radical prostatectomy stereotactic body radiotherapy.

We established prognostic nomograms incorporating prostate-specific membrane antigen (PSMA) positron emission tomography (PET) parameters standardised…

To our knowledge, this is the first randomised trial for metachronous PET-detected nodal recurrences comparing two local treatment approaches (MDT and ENRT) in combination with 6 months of androgen de...

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO G...

Abstract. Early cancer diagnosis is crucial but challenging owing to the lack of reliable biomarkers that can be measured using routine clinical methods. The identification of biomarkers for early det...

177Lu-rhPSMA-10.1 is a novel radiohybrid prostate-specific membrane antigen (PSMA)–targeted radiopharmaceutical therapy for prostate cancer. We conducted preclinical analyses on non–tumor-bearing BALB...

This Review provides an overview of the main targetable surface proteins in prostate cancer, defined as the surfaceome, discussing the mechanisms of action and efficacy of currently available drugs ta...

On March 28, 2025, the Food and Drug Administration expanded the indication for lutetium Lu 177 vipivotide tetraxetan (Pluvicto).

This randomized, noninferiority trial of biopsy-naive men compares the detection of Gleason Grade Group ≥2 prostate cancer using microultrasonography-guided and MRI fusion-guided biopsy.

In this post-hoc analysis of a phase 3 randomized controlled trial comparing apalutamide versus placebo in metastatic castration-sensitive prostate cancer, patients with two or less bone metastases h...

Trials comparing moderately hypofractionated radiotherapy (MHFRT) to conventionally-fractionated radiotherapy (CFRT) for prostate cancer have varied c…

This cohort study evaluates the time necessary to accurately document a persistent prostate-specific antigen level after radical prostatectomy.

Prostate Cancer and Prostatic Diseases - Impact of stereotactic body radiotherapy after progression in castrate resistant prostate cancer patients undergoing first line abiraterone treatment. A...

Selection of patients harboring mutations in homologous recombination repair (HRR) genes for treatment with a PARP inhibitor (PARPi) is challenging in…

YouTube video by OncoAlert 360

This cohort study assesses the feasibility and safety of a community-based magnetic resonance imaging (MRI) diagnostic strategy in men with suspected prostate cancer using 3-year active monitoring.

AbstractBackground. It is unknown if a period of active surveillance before prostatectomy for prostate cancer (PCa) worsens functional outcomes. The aim of

This cohort study examines prostate cancer–specific mortality and metastatic prostate cancer risks after age 70 in men who had undergone recent prostate-specific antigen (PSA) screening.

This cohort study examines the trends in prostate cancer incidence and mortality rates in California by stage, age, race and ethnicity, and region of California.

Inherited genetic mutations can significantly increase the risk for prostate cancer (PC), may be associated with aggressive disease and poorer outcomes, and can have hereditary cancer implications fo...

Prostate Cancer and Prostatic Diseases - Is there a role of PSMA-PET in focal therapy planning and follow-up?

In the phase 3 IPATential150 trial, ipatasertib addition to abiraterone significantly reduced the risk of disease progression in men with metastatic c…

PURPOSEPrior noncontemporary studies showed that oral cyclophosphamide is an active treatment of metastatic castration-resistant prostate cancer (mCRPC). However, cyclophosphamide is currently underut...

Arce-Gallego et al. integrate next-generation sequencing with a RAD51 immunofluorescence assay to assess HRR function in advanced prostate cancer. They link RAD51-IF scores to mutations in HRR genes, ...

Recent randomized controlled trials have demonstrated the efficacy of five-fraction stereotactic body radiotherapy (5F-SBRT) for prostate cancer (PC),…

Men appreciate prostate cancer screening opportunities, but their participation is influenced by practical, personal, and psychological factors. Clear communication about the benefits and risks of tes...

AbstractBackground. There has been a wide range in incidence of prostate-specific antigen (PSA) persistence and relapse after radical prostatectomy (RP) fo

Treatment options for localized prostate cancer have been expanded by FDA-approval of High-Intensity Focused Ultrasound (HIFU). Prostate cancer typica…

Selection of patients harboring mutations in homologous recombination repair (HRR) genes for treatment with a PARP inhibitor (PARPi) is challenging in…

Background Most patients with prostate cancer inevitably progress to castration-resistant prostate cancer (CRPC), at which stage chemotherapeutics like docetaxel become the first-line treatment. Howev...

SABR is growingly accepted for the treatment of localized prostate cancer with recent randomized trials showing noninferiority compared with conventional or moderately hypofractionated radiation thera...

The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!

Objective The objective of this study is to analyse the perspectives of screening candidates and healthcare professionals on shared decision-making (SDM) in prostate cancer (PCa) screening using the p...

Researchers shed light on the genes that could be linked to the high mortality rates of prostate cancer among men of African descent.